Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 2-Part, Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Subjects

Trial Profile

A 2-Part, Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2018

At a glance

  • Drugs JNJ 55375515 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 28 Sep 2018 Status changed from recruiting to completed.
    • 31 Jul 2018 Planned primary completion date changed from 10 Jul 2018 to 10 Sep 2018.
    • 29 Jun 2018 Planned End Date changed from 10 Jul 2018 to 10 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top